Working… Menu

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00089427
Recruitment Status : Completed
First Posted : August 6, 2004
Last Update Posted : July 4, 2011
Information provided by:
INSYS Therapeutics Inc

Brief Summary:
This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor site after the tumor is surgically removed (resection). In addition, the patient will receive radiation therapy and may or may not be treated with oral temozolomide.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Anaplastic Astrocytoma Oligoastrocytoma Drug: IL13-PE38QQR Procedure: Surgery for placement Procedure: Radiation therapy Drug: Temozolomide with radiation therapy Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma
Study Start Date : July 2004
Actual Primary Completion Date : July 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be ≥18 years old.
  • Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter.
  • Patients must be able to have catheters placed within 14 days of tumor resection (including a planned Gross Total Resection following an initial biopsy or subtotal resection)
  • Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA.
  • Patients must be in adequate general condition and meet the following criteria:
  • a. Karnofsky Performance Scale score ≥ 70
  • b. Adequate hematologic status:

    • Absolute neutrophil count ≥ 1,500/mm³
    • Hemoglobin ≥ 10 gm/dL
    • Platelets ≥ 100,000/mm³
    • PT & aPTT within institutional limits of normal
  • Female patients must not be pregnant or breast-feeding.
  • Patients must practice an effective method of birth control during the study and for 60 days beyond the last day of infusion.
  • Patients must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure.

Exclusion Criteria:

  • Patients with residual contrast-enhancing tumor crossing the midline, multifocal tumor not amenable to gross total resection or non-parenchymal tumor dissemination (e.g., subependymal or leptomeningeal).
  • Patients with clinically significant increased ICP (e.g., impending herniation), uncontrolled seizures or requirement for immediate palliative treatment.
  • Patients who have received any prior anti-tumor treatment (other than corticosteroids) including any investigational agents.
  • Patients with any metallic prosthesis that would prevent MRI and/or MRS scanning procedures of the brain.
  • Patients unwilling or unable to follow protocol requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00089427

Layout table for location information
United States, California
University of California San Francisco - Dept. of Neurological Surgery
San Francisco, California, United States, 94143
United States, North Carolina
Carolina Neurosurgery & Spine Assoc.
Charlotte, North Carolina, United States, 28204
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cleveland Clinic Foundation Department of Neurological Surgery
Cleveland, Ohio, United States, 44195
United States, Texas
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Virginia
University of Virginia Health Systems - Department of Neurological Surgery
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
INSYS Therapeutics Inc
Layout table for additonal information Identifier: NCT00089427    
Obsolete Identifiers: NCT00105014
Other Study ID Numbers: IL13PEI-106-R01
First Posted: August 6, 2004    Key Record Dates
Last Update Posted: July 4, 2011
Last Verified: April 2011
Keywords provided by INSYS Therapeutics Inc:
brain tumor
malignant glioma
brain neoplasm
central nervous system
glioblastoma multiforme
anaplastic astrocytoma
convection-enhanced delivery
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents